533 related articles for article (PubMed ID: 33638807)
1. MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19.
Hum C; Loiselle J; Ahmed N; Shaw TA; Toudic C; Pezacki JP
Drugs; 2021 Apr; 81(5):517-531. PubMed ID: 33638807
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs in the development of potential therapeutic targets against COVID-19: A narrative review.
Ahmed JQ; Maulud SQ; Dhawan M; Priyanka ; Choudhary OP; Jalal PJ; Ali RK; Tayib GA; Hasan DA
J Infect Public Health; 2022 Jul; 15(7):788-799. PubMed ID: 35751930
[TBL] [Abstract][Full Text] [Related]
3. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
4. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
5. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
[TBL] [Abstract][Full Text] [Related]
7. A global treatments for coronaviruses including COVID-19.
Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M
J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467
[TBL] [Abstract][Full Text] [Related]
8. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Khare P; Sahu U; Pandey SC; Samant M
Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
[TBL] [Abstract][Full Text] [Related]
9. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 may regulate cellular responses through depletion of specific host miRNAs.
Bartoszewski R; Dabrowski M; Jakiela B; Matalon S; Harrod KS; Sanak M; Collawn JF
Am J Physiol Lung Cell Mol Physiol; 2020 Sep; 319(3):L444-L455. PubMed ID: 32755307
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
Anand P; Puranik A; Aravamudan M; Venkatakrishnan AJ; Soundararajan V
Elife; 2020 May; 9():. PubMed ID: 32452762
[TBL] [Abstract][Full Text] [Related]
12. Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries.
Marian AJ
Cardiovasc Pathol; 2021; 50():107278. PubMed ID: 32889088
[TBL] [Abstract][Full Text] [Related]
13. The role of microRNAs in modulating SARS-CoV-2 infection in human cells: a systematic review.
Marchi R; Sugita B; Centa A; Fonseca AS; Bortoletto S; Fiorentin K; Ferreira S; Cavalli LR
Infect Genet Evol; 2021 Jul; 91():104832. PubMed ID: 33812037
[TBL] [Abstract][Full Text] [Related]
14. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
Joseph J; Karthika T; Das VRA; Raj VS
Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
[TBL] [Abstract][Full Text] [Related]
15. Plant MicroRNA Potential in Targeting Sars-CoV-2 Genome Offering Efficient Antiviral MiRNA-Based Therapies.
Hajieghrari B; Rahmanian-Koshkaki S
Microrna; 2022; 11(3):245-262. PubMed ID: 35984027
[TBL] [Abstract][Full Text] [Related]
16. Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses.
Huang T; Sun L; Kang D; Poongavanam V; Liu X; Zhan P; Menéndez-Arias L
Adv Exp Med Biol; 2021; 1322():219-260. PubMed ID: 34258743
[TBL] [Abstract][Full Text] [Related]
17. Potential inhibitors of SARS-CoV-2: recent advances.
Jamalipour Soufi G; Iravani S
J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953
[TBL] [Abstract][Full Text] [Related]
18. An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension.
Fuchs E; Rudnik-Jansen I; Dinesen A; Selnihhin D; Mandrup OA; Thiam K; Kjems J; Pedersen FS; Howard KA
Acta Biomater; 2022 Nov; 153():411-418. PubMed ID: 36162760
[TBL] [Abstract][Full Text] [Related]
19. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
20. Cellular microRNAs target SARS-CoV-2 spike protein and restrict viral replication.
Vaddadi K; Gandikota C; Huang C; Liang Y; Liu L
Am J Physiol Cell Physiol; 2023 Aug; 325(2):C420-C428. PubMed ID: 37399496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
